Actively Recruiting
Clinical Evaluation of a Nutraceutical Supplement for Hair Growth, Hair Loss and Skin Improvement in Human Volunteers
Led by Olistic Research Labs S.L. · Updated on 2026-01-29
60
Participants Needed
1
Research Sites
78 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical trial is to evaluate the efficacy and safety of Olistic Next Women, a nutraceutical supplement, in women experiencing beginning of female pattern hair loss (FPHL).This 6-month, double-blind, placebo-controlled, 2:1 randomized clinical trial investigates whether daily supplementation with Olistic Next Women leads to significant improvements in hair parameters compared to placebo. The study also monitors the tolerability and safety of the product throughout the intervention.
CONDITIONS
Official Title
Clinical Evaluation of a Nutraceutical Supplement for Hair Growth, Hair Loss and Skin Improvement in Human Volunteers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female subjects with female pattern hair loss
- Aged between 45 and 65 years
- Signed informed consent
- In good general health for age without active diseases that would exclude participation based on investigator's opinion
You will not qualify if you...
- Known allergy or intolerance to any ingredients of the study product
- Chronic wounds, erosions, infected skin, or inflammation in the study area
- Suspected non-compliance with study requirements
- Late onset acne or hirsutism
- Use of systemic immunosuppressants within 12 months prior to study
- Use of topical or systemic products that could affect study results (e.g., topical minoxidil, caffeine, hormone-influencing drugs)
- Hormone replacement therapy (HRT) initiated less than 6 months before screening
- Exclusively or mainly vegan diet
- Known gluten or lactose intolerance
- Hyperthyroidism
- Non-stable hypothyroidism with abnormal thyroid-stimulating hormone (TSH) levels
- Other scalp diseases affecting study results (e.g., Lichen planus, Psoriasis capitis, scarring alopecia)
- Participation in any clinical trial currently or within the last 30 days
- Abnormal baseline blood test results for zinc, ferritin, selenium, folic acid, vitamin B12, TSH, or CRP
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CentroDerm
Wuppertal, Barmen, Germany, 42287
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here